Prader Willi Syndrome: Emerging Therapies
Prader-Willi syndrome is a rare genetic condition characterized by physical and behavioral problems, including an uncontrollable appetite.
A recent breakthrough came with the approval of VYKAT XR, developed by Soleno Therapeutics, which addresses hyperphagia using diazoxide choline to increase satiety.
It is now the first and only approved drug by the U.S. Food and Drug Administration (FDA) to treat hyperphagia.
Several other treatments are currently in clinical trials, offering hope for the Prader-Willi syndrome community with diverse approaches to managing symptoms.
Author's summary: New therapies for Prader-Willi syndrome are emerging.